TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clinuvel Pharmaceuticals ( (AU:CUV) ) just unveiled an update.
CLINUVEL PHARMACEUTICALS LIMITED has issued 77,110 fully paid ordinary shares at no issue price, as announced in compliance with the Corporations Act 2001. This strategic move is part of the company’s ongoing efforts to strengthen its market position and ensure compliance with regulatory requirements, potentially impacting its operational capabilities and stakeholder interests.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
CLINUVEL PHARMACEUTICALS LIMITED is a global specialty pharmaceutical group focused on developing and commercializing treatments for genetic, metabolic, systemic, and life-threatening acute disorders, as well as healthcare solutions for specialized populations. The company is a pioneer in photomedicine and melanocortin peptides, with its lead therapy, SCENESSE®, approved for use in multiple regions including Europe, the USA, Israel, and Australia.
Average Trading Volume: 140,787
Technical Sentiment Signal: Sell
Current Market Cap: A$601.5M
Find detailed analytics on CUV stock on TipRanks’ Stock Analysis page.